[go: up one dir, main page]

AR115878A1 - SPECIFIC FUSION PROTEINS FOR CD137 AND PD-L1 - Google Patents

SPECIFIC FUSION PROTEINS FOR CD137 AND PD-L1

Info

Publication number
AR115878A1
AR115878A1 ARP190102165A ARP190102165A AR115878A1 AR 115878 A1 AR115878 A1 AR 115878A1 AR P190102165 A ARP190102165 A AR P190102165A AR P190102165 A ARP190102165 A AR P190102165A AR 115878 A1 AR115878 A1 AR 115878A1
Authority
AR
Argentina
Prior art keywords
fusion proteins
compositions
nucleic acid
acid molecules
methods
Prior art date
Application number
ARP190102165A
Other languages
Spanish (es)
Inventor
Alix Scholer-Dahirel
Lucia Pattarini
Marina Pavlidou
Janet Peper
Marlon Hinner
Aiba Rachida Bel
Shane Olwill
Christine Rothe
Original Assignee
Pieris Pharmaceuticals Gmbh
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pieris Pharmaceuticals Gmbh, Servier Lab filed Critical Pieris Pharmaceuticals Gmbh
Publication of AR115878A1 publication Critical patent/AR115878A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La descripción provee proteínas de fusión específicas tanto para CD137 como para PD-L1, las cuales pueden ser utilizadas para coestimular activación de linfocitos de una manera dependiente de la diana-PD-L11. Dichas proteínas de fusión pueden ser utilizadas en muchas aplicaciones farmacéuticas, por ejemplo como agentes anti-cáncer y/o inmunomoduladores para el tratamiento o prevención de enfermedades humanas tales como una variedad de tumores. La presente descripción también se refiere a métodos de preparar las proteínas de fusión descriptas en la presente así como composiciones que comprenden dichas proteínas de fusión. La presente descripción también se refiere a moléculas de ácido nucleico que codifican dichas proteínas de fusión y a métodos para la generación de dichas proteínas de fusión y moléculas de ácido nucleico. Además, la solicitud describe usos diagnósticos y/o terapéuticos de dichas proteínas de fusión así como composiciones que comprenden una o más de dichas proteínas de fusión.The disclosure provides specific fusion proteins for both CD137 and PD-L1, which can be used to costimulate lymphocyte activation in a PD-L11-target-dependent manner. Said fusion proteins can be used in many pharmaceutical applications, for example as anti-cancer and / or immunomodulatory agents for the treatment or prevention of human diseases such as a variety of tumors. The present description also relates to methods of preparing the fusion proteins described herein as well as compositions comprising said fusion proteins. The present description also relates to nucleic acid molecules encoding said fusion proteins and to methods for the generation of said fusion proteins and nucleic acid molecules. Furthermore, the application describes diagnostic and / or therapeutic uses of said fusion proteins as well as compositions comprising one or more of said fusion proteins.

ARP190102165A 2018-07-31 2019-07-31 SPECIFIC FUSION PROTEINS FOR CD137 AND PD-L1 AR115878A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18186445 2018-07-31

Publications (1)

Publication Number Publication Date
AR115878A1 true AR115878A1 (en) 2021-03-10

Family

ID=63254499

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190102165A AR115878A1 (en) 2018-07-31 2019-07-31 SPECIFIC FUSION PROTEINS FOR CD137 AND PD-L1

Country Status (2)

Country Link
AR (1) AR115878A1 (en)
MA (1) MA53321B1 (en)

Also Published As

Publication number Publication date
MA53321A (en) 2022-01-26
MA53321B1 (en) 2023-08-31

Similar Documents

Publication Publication Date Title
CL2021000207A1 (en) New fusion proteins specific for cd137 and pd-l1
CL2017002767A1 (en) New specific proteins for cd137.
MX390894B (en) ANTI-CANCER FUSION POLYPEPTIDE.
EP4378962A3 (en) Anti-cancer fusion polypeptide
MX2021010039A (en) Novel fusion proteins specific for cd137 and gpc3.
AU2018240515A1 (en) Nucleic acids encoding CRISPR-associated proteins and uses thereof
CR11817A (en) ANTI-FACTOR D HUMANIZED ANTIBODIES AND THEIR USES
DOP2017000191A (en) NEW SPECIFIC PROTEINS FOR PIOVERDINA AND PIOQUELINA
BR112018016281A2 (en) protease activatable bispecific t-cell activating molecule, idiotype-specific polypeptide, pharmaceutical composition, uses of the bispecific molecule and method of treating a disease in an individual
HK1254450A1 (en) Novel fusion polypeptide specific for lag-3 and pd-1
BR112016022553A2 (en) COMPOUNDS AND METHODS FOR TRANSMEMBRANE DELIVERY OF MOLECULES?
EP4349854A3 (en) Pd1-cd28 fusion proteins and their use in medicine
AR063760A1 (en) ANTI-FACTOR D HUMANIZED ANTIBODIES AND USES OF THE SAME
BR112014019459A8 (en) DCIM-BINDING PROTEINS AND USES THEREOF
BR112017026292A2 (en) lipocalin mutein, nucleic acid molecule, expression vector, host cell, lipocalin mutein production method, methods of binding lag-3 in patients, stimulating immune reaction in patients, inducing t lymphocyte proliferation, interfere with human lag-3 binding and detection of the presence of lag-3, pharmaceutical composition, immunoconjugate, mutein use and analytical or diagnostic kit
MX2017009767A (en) Novel proteins specific for angiogenesis.
BR112014027981A2 (en) fumagilol type compounds and methods of production and use thereof
MX2019014448A (en) IMMUNOGLOBULINS BINDING TO MMP13.
BR112018017174A2 (en) amino acid and peptide conjugates and conjugation process
BR112017012588B8 (en) Bicyclic heteroaryl-heteroaryl compounds of benzoic acid, their uses, pharmaceutical compositions, methods of preparation thereof and methods for causing or promoting neurite outgrowth, neurite outgrowth and/or neurite regeneration and for activating the retinoic acid beta receptor
AR095387A1 (en) SPECIFIC PROTEINS FOR BAFF AND FOR B7RP1 AND ITS USES
BR112017024714A2 (en) methods for preparing modified von willebrand factor
AR115878A1 (en) SPECIFIC FUSION PROTEINS FOR CD137 AND PD-L1
MX2023006830A (en) Immunocytokine for activating human il-10ra receptor and use thereof.
AR127728A1 (en) NEW FUSION PROTEIN SPECIFIC FOR OX40 AND PD-L1

Legal Events

Date Code Title Description
FA Abandonment or withdrawal